FDA Determines Regulatory Review Period for Aldara Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for Aldara (4,689,338) and is publishing this notice as required by law. The FDA made this determination due to a patent extension application submitted to the Commissioner of Patents and Trademarks, Department of Commerce, for the human drug product.